Background: Arginine depletion is a putative target in hepatocellular carcinoma (HCC). HCC often lacks argininosuccinate synthetase, a citrulline to arginine-repleting enzyme. ADI-PEG 20 is a cloned arginine degrading enzyme-arginine deiminaseconjugated with polyethylene glycol. The goal of this study was to evaluate this agent as a potential novel therapeutic for HCC after first line systemic therapy.
Introduction
Arginine, a nonessential amino acid in humans, is synthetized from citrulline via argininosuccinate synthetase (ASS1) and argininosuccinate lyase [1] . Hepatocellular carcinoma (HCC) cells lack ASS1, and thus cannot metabolize citrulline into arginine [2, 3] . ADI-PEG 20 is an arginine deiminase enzyme, cloned from Mycoplasma hominis, produced in Escherichia coli (E. coli) and conjugated with polyethylene glycol. It turns external supplies of arginine into citrulline [4] . Degrading arginine external sources via ADI-PEG 20, combined with the lack of ASS1, renders arginine depletion a putative target for HCC.
Three phase II clinical trials have evaluated ADI-PEG 20 in advanced HCC, and have collectively suggested an improvement in survival [2, 5, 6] , across different etiologies of HCC [2] .
Patients and methods
This was a www.clinicaltrials.gov registered (NCT 01287585) multiinstitutional, randomized, placebo-controlled phase III clinical trial, that was reviewed and approved by the Institutional Review Board (IRB). Written informed consent was obtained from each patient.
Patients' eligibility
Patients 18 years of age, with unresectable locally advanced, or metastatic histologically confirmed HCC, with at least one measurable lesion by RECIST 1.1 [7] , and who had received at least one prior systemic therapy with documented progression of disease or adverse events that resulted in discontinuance of that therapy were eligible. Patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and a Child-Pugh score up to B7. Adequate hematologic function, renal and hepatic function (total bilirubin 3 mg/dl, albumin 2.8 g/dl, AST/ALT 5 times the upper limit of normal) were required. Serum uric acid 8 mg/dl possible due to hyperuricemia with ADI-PEG 20 [2, 5, 6] was required. Antihyperuricemic treatment was allowed, and dietary restrictions for arginine-rich foods were recommended.
Ineligibility included history of untreated variceal bleed within 3 months, serious inter-current illnesses, known brain metastases, clinically significant other medical history, known HIV infection, pregnant women, and/or other malignancies that might have affected outcome.
Treatment plan
Eligible patients were randomized (2 : 1) to receive either weekly ADI-PEG 20 18 mg/m 2 or placebo intramuscularly (i.m.) in a double-blinded fashion, with best supportive care. One cycle consisted of four weekly treatments. Patients were evaluated every other week, and assessed for adverse events weekly. Computed tomography (CT) or magnetic resonance imaging (MRI) scans were carried out every three cycles. Patients continued treatments except for unacceptable adverse events, death, or progression of disease.
Study objectives
The primary outcome was overall survival (OS). Secondary objectives included safety and tolerability using the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.02, response rate, progression-free survival (PFS), and time to progression (TtP). The latter two defined as the time from randomization till radiologic disease progression or death, and the time from randomization to the date of progression, respectively. Disease control rate was defined as the percentage of patients with confirmed CR, PR, or stable disease (SD).
Immunogenicity assay
Peripheral blood anti-ADI-PEG 20 antibody titers were assessed using a validated single-tier semi-quantitative enzyme-linked immunosorbent assaybased assay [8] . Microtiter plates were coated with ADI-PEG 20. Diluted human plasma samples were added, incubated for 60 min, and then treated with a goat antihuman immunoglobulin A þ immunoglobulin G þ immunoglobulin M /horseradish peroxidase conjugate. Tetramethy lbenzidine was added to the plate, react and then the absorbance at 450 nm was recorded and used as reference. The titer of a sample was based on the highest dilution that yielded a positive signal.
Pharmacodynamic assay
Peripheral blood arginine levels were measured in samples at baseline and at the start of each cycle using liquid chromatography [highperformance liquid chromatography (HPLC)] with tandem mass spectrometric detection. Arginine and an isotopically labelled internal control were extracted from human plasma samples by protein precipitation. The supernatant was loaded on to a Venusil ASB C18 column. The mobile phase was 0.1% formic acid in water : acetonitrile (95 : 5, v : v). Detection was carried out with positive ion electrospray using a Sciex API 5000. The ratio of the peak areas arising from the arginine and isotopically labelled internal standard was used to quantify the arginine level.
Pharmacokinetic assay
Peripheral blood ADI-PEG 20 levels were measured in samples at baseline and at the start of each cycle using a fluorometric enzyme activity-based assay designed to detect the conversion of arginine to citrulline and ammonia; and the reaction of ammonia with o-phthaldialdehyde (OPA) to produce a fluorescent isoindole-derivative [9] . Plasma samples were added to assay buffer, followed by arginine, react, followed by development reagent (OPA and reducing agent). The plate was read using a fluorometric plate reader with excitation set at 405 nm and emission set at 460 nm, with known amounts of ADI-PEG 20 used to generate a calibration curve.
Statistical analyses
Statistical analyses were based on intent-to-treat populations. The safety population comprised all patients who received at least one dose of study medication.
Median OS was estimated to be 4 months after progressing on sorafenib [10, 11] . An improvement of 40% resulting in a median OS to 5.6 months was deemed to be clinically significant. Estimated 633 accrued patients were needed with 487 deaths to demonstrate an overall onesided type I error rate (a) of 0.025, and an overall type II error rate (b) of 0.07. Treatments were compared using a log-rank test stratified by the region Asia versus non-Asia and by prior sorafenib exposure. OS, PFS, and TtP were summarized using the Kaplan-Meier method, with 95% confidence intervals analyzed by treatment group.
Safety, tolerability, adverse events, and all pharmacokinetic and pharmacodynamic analyses were summarized descriptively. The relationship between anti-ADI-PEG 20 antibodies and changes in arginine was assessed using Pearson's q.
The relationship between arginine depletion (based on blood samples taken at weeks 4, 8, 12, and 16) and OS was studied post hoc on the ADI-PEG 20 group.
ASS1 expression induced by sorafenib in HCC cell lines
ASS1 protein expression in both untreated and drug treated human HCC cell lines was assessed by western blot as described [12] .
Results

Patients' disposition
A total of 854 patients were assessed for eligibility and 635 unique patients were randomly assigned to receive ADI-PEG 20 (n ¼ 424) or placebo (n ¼ 211) (Figure 1 ).
Demographics
Demographics were as detailed in Table 1 . A total of 332 (52.3%) patients had hepatitis B as etiology and 338 (53.2%) were accrued in Asia. The group of prior sorafenib failure encompassed 549 (86.5%).
Treatment
The median number of doses administered of ADI-PEG 20 was 11 (range 0-145) versus 11 (0-98) for placebo, with a duration of exposure of 10 (range 0-146) and 11 (range 0-109) weeks, respectively.
Safety and tolerability
The incidence of adverse events was similar between the two treatment groups (Table 2 ). There was no statistical difference in the between the two groups. Fatigue was the most frequent adverse event. Grade 3 skin puritis or rash was limited to 1 (0.2%) and 2 (1%) patients who received ADI-PEG 20 and placebo, respectively. Two cases of anaphylaxis occurred after the third and eighth injections, of ADI-PEG 20, respectively. In the first case, there was no anti-ADI-PEG 20 antibody detected. In the second case, it was 10 3 . There were 64 (15.2%) deaths in the ADI-PEG 20 group that occurred within 30 days of the last dose of study drug, versus 22 (10.5%) in placebo group. Deaths due to causes other than disease progression were 22/64 (34.4%) in the ADI-PEG 20 group and 12/22 (54.5%) in the placebo group. These included 10 gastrointestinal bleeds (6 in the ADI-PEG 20 group and 4 in the placebo group); 8 liver failures (6 and 2, respectively); and 1 intracranial hemorrhage, 1 brain stem infarction, and 1 tumor embolus, all in the ADI-PEG 20 group. One cardiac arrest on ADI-PEG 20 and 4 respiratory failures (2 in each group) were reported. Sepsis/infection occurred in three (2 in the ADI-PEG 20 group and 1 in the placebo group). Four patients sustained general health deterioration (1 in the ADI-PEG 20 group and 3 in the placebo group). One patient in the ADI-PEG 20 group died of unexplained abdominal pain.
Outcome
The median OS (Figure 2A) Figure S1 , available at Annals of Oncology online. There was no significant difference in OS for the treatment and placebo groups when the geographical regions, or when prior sorafenib failure or nonsorafenib subgroups were analyzed. For the nonsorafenib group, the v 2 value for the comparison was 2.84, P ¼ 0.092. The median PFS as depicted in Figure 2B Two and six partial responses were reported for the ADI-PEG 20 and placebo groups, respectively.
There was no difference in AFP (supplementary Table S1 , available at Annals of Oncology online) and AFP decrease did not correlate with arginine levels (supplementary Table S2 , available at Annals of Oncology online).
Immunogenicity
The median baseline value for anti-ADI-PEG 20 antibodies was 0 in both groups. The median post baseline change was an increase to a titer of 2 around 8 weeks with a plateau at a titer of 3 at 12 weeks in the ADI-PEG 20 group. The titer remained 0 in the placebo group. Changes from baseline in anti-ADI-PEG 20 antibodies and blood arginine levels were correlated at all time points tested (weeks 2, 4, 8, 12, 16; P < 0.0001). Levels of anti-ADI-PEG 20 antibodies did not correlate with adverse events. No attempt was made to discern neutralizing antibodies from non-neutralizing antibodies.
Pharmacokinetics
In the ADI-PEG 20 group, the mean blood ADI-PEG 20 levels were highest at weeks 2 and 4, and then decreased to a plateau level at week 12, to 45% of the highest levels. This was commensurate with the development of anti-ADI-PEG 20 antibodies.
Pharmacodynamics
Circulating arginine level markedly decreased after the first dose of ADI-PEG 20. The median arginine level remained depleted (reached and remained below 10 lM post ADI-PEG 20 dosing) for 8 weeks (data not shown).
To determine whether there was a relationship between arginine depletion and OS, a post hoc analysis was carried out at each of the specified timepoints (4, 8, 12 , and 16 weeks). ADI-PEG 20 treated patients were divided into an arginine depletion, those who no longer met the arginine depletion as defined at the specified timepoint. Patients who had died, progressed, withdrawn consent, or were otherwise unable to have a blood draw at the specified timepoint were excluded (supplementary Table S3 , available at Annals of Oncology online). At all four timepoints tested, the patients with arginine depletion trended to have improved OS.
Discussion
ADI-PEG 20 at a dose of 18 mg/m 2 did not show an improvement in OS versus placebo in patients with advanced HCC who had failed prior systemic therapy. Patients with arginine depletion trended to have improved OS, similar to prior study [2] . In the post hoc analysis as there may be a selection bias as some patients came off study early due to progression and thus could no longer contribute to the pharmacodynamic analysis. This analysis might also be affected by the next line of therapy. Although antidrug antibodies were determined, neutralizing antibodies were not. A general lack of correlation between neutralizing antibodies and arginine levels, and the possibility of still present efficacy despite the presence of neutralizing antibodies for ADI-PEG 20 has been noted [2, 13] , similar to other agents [14] . Strategies to prolong ADI-PEG 20 induced arginine suppression include: (i) an increased dose of ADI-PEG 20 (36 mg/m 2 ) [15] , (ii) combination with cytotoxic agents which may blunt the immune response to ADI-PEG 20, and (iii) developing a new ADI that would not be so quickly neutralized by antibodies. This latter approach is currently under investigation, and would mirror the success observed with asparaginase from Erwinia chrysanthemi in patients with acute lymphocytic leukemia (ALL) who have developed antibodies to E. coli asparaginase [16] , as well as by developing a new formulation [17] .
Local injection site reactions, rash, pruritus and anaphylaxis were expected [18, 19] , and at occurred at a rate of 0.4%. This compares favorably with other pegylated non-human enzymes used in the treatment of patients [20, 21] . Local injection site reactions in the placebo control group were consistent with the i.m. injection of the placebo solution.
The cases of brain stem infarction and intracerebral hemorrhage occurred in the ADI-PEG 20 treated group, thus with an occurrence rate of 0.4%. In cirrhotic patients intracerebral hemorrhage are similarly observed [22, 23] .
Respiratory failure, consistent with hepatopulmonary syndrome, is a well-known complication of cirrhosis, same for infection [24, 25] .
While this study was ongoing an experiment was conducted across multiple HCC cell lines which demonstrated an increase in ASS1 expression in some cell lines treated with sorafenib (supplementary Figure S2 , available at Annals of Oncology online). Considering that 86% of patients received prior sorafenib, upregulation of ASS1 expression may have contributed to the lack of efficacy in the patient population in this study.
At the time of the design of the study, the 4 months median OS anticipated for the placebo group seemed reasonable. In retrospect, it would be hard to justify nowadays with improved performance status and a favorable Child-Pugh population selected for clinical trials. The reported herein 7.4 months median OS for the placebo group is commensurate with current data [26] .
Capitalizing on the attributes that may help potentiate the efficacy of ADI-PEG 20 would be critical. Another arginine deprivation approach in HCC has been investigated with pegylated recombinant human arginase [27] .
In summary, ADI-PEG 20 at the dose of 18 mg/m 2 proved to be ineffective in prolonging OS in patients with advanced HCC who failed prior therapy. However, those with arginine depletion from ADI-PEG 20 were observed to have a superior OS to those who did not achieve prolonged depletion. New studies of ADI-PEG 20 are currently focused on maximizing arginine depletion through elucidating and testing potential synergistic effects and on modulating its antigenic structure as well as formulation.
